Arrowstreet Capital Limited Partnership grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 79.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 174,916 shares of the specialty pharmaceutical company's stock after buying an additional 77,393 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.32% of Supernus Pharmaceuticals worth $6,325,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in SUPN. Vanguard Group Inc. grew its stake in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after purchasing an additional 22,852 shares during the last quarter. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after acquiring an additional 74,438 shares in the last quarter. American Century Companies Inc. raised its stake in Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after acquiring an additional 95,777 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after purchasing an additional 40,968 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Supernus Pharmaceuticals by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock worth $14,449,000 after acquiring an additional 27,134 shares during the period.
Insider Activity at Supernus Pharmaceuticals
In related news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,104 shares of company stock valued at $440,263. Corporate insiders own 9.30% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on SUPN shares. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
View Our Latest Stock Analysis on Supernus Pharmaceuticals
Supernus Pharmaceuticals Price Performance
Supernus Pharmaceuticals stock traded up $0.60 during mid-day trading on Friday, hitting $31.67. The company's stock had a trading volume of 407,129 shares, compared to its average volume of 492,037. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The firm's 50 day moving average is $33.52 and its 200 day moving average is $35.04. The company has a market cap of $1.77 billion, a PE ratio of 29.60 and a beta of 0.90.
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
